Evidence map›Paper›PMID 34673531›Full record

ArticleJMIR public health and surveillance2021

Implementation of the World Health Organization Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study Using National Surveillance Data.

Susan Nabadda, Francis Kakooza, Reuben Kiggundu, Richard Walwema, Joel Bazira, Jonathan Mayito, Ibrahimm Mugerwa, Musa Sekamatte, Andrew Kambugu, Mohammed Lamorde and 2 more

Open access · goldAbstract read
In one paragraph

Article in JMIR public health and surveillance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Trends of Antibiotic Resistance in ESKAPE Pathogens in Mbarara Regional Referral Hospital (2015-2022), South Western, Uganda.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Co-Infection of SARS-CoV-2 andDiagnostics (Basel, Switzerland) · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Susan Nabadda *Laboratory and Diagnostics Services Department, Ministry of Health, Kampala, Uganda.ORCID 0000-0003-2357-2530
Francis Kakooza *Global Health Security Department, Infectious Diseases Institute, Kampala, Uganda.ORCID 0000-0003-4047-6620
Reuben KiggunduGlobal Health Security Department, Infectious Diseases Institute, Kampala, Uganda.ORCID 0000-0001-6141-9436
Richard WalwemaGlobal Health Security Department, Infectious Diseases Institute, Kampala, Uganda.ORCID 0000-0003-0870-9009
Joel BaziraDepartment of Medical Microbiology, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0001-7600-7514
Jonathan MayitoGlobal Health Security Department, Infectious Diseases Institute, Kampala, Uganda.ORCID 0000-0001-9611-2178
Ibrahimm MugerwaLaboratory and Diagnostics Services Department, Ministry of Health, Kampala, Uganda.ORCID 0000-0003-4462-2867
Musa SekamatteAntimicrobial Resistance Sub-Committee, National One Health Platform, Kampala, Uganda.ORCID 0000-0001-9312-6873
Andrew KambuguGlobal Health Security Department, Infectious Diseases Institute, Kampala, Uganda.ORCID 0000-0002-3075-0211
Mohammed LamordeGlobal Health Security Department, Infectious Diseases Institute, Kampala, Uganda.ORCID 0000-0003-2218-6822
Henry KajumbulaAntimicrobial Resistance Sub-Committee, National One Health Platform, Kampala, Uganda.ORCID 0000-0002-2075-0007
Henry MwebasaLaboratory and Diagnostics Services Department, Ministry of Health, Kampala, Uganda.ORCID 0000-0002-4155-9009
Infectious Diseases Institute · UGMinistry of Health · UGMakerere University · UGMbarara University of Science and Technology · UGUnited States Agency for International Development · US

Funding

CGH CDC HHS U2G GH001744
6 · The paper itself

Abstract

backgroundAntimicrobial resistance (AMR) is an emerging public health crisis in Uganda. The World Health Organization (WHO) Global Action Plan recommends that countries should develop and implement National Action Plans for AMR. We describe the establishment of the national AMR program in Uganda and present the early microbial sensitivity results from the program.

objectiveThe aim of this study is to describe a national surveillance program that was developed to perform the systematic and continuous collection, analysis, and interpretation of AMR data.

methodsA systematic qualitative description of the process and progress made in the establishment of the national AMR program is provided, detailing the progress made from 2015 to 2020. This is followed by a report of the findings of the isolates that were collected from AMR surveillance sites. Identification and antimicrobial susceptibility testing (AST) of the bacterial isolates were performed using standard methods at both the surveillance sites and the reference laboratory.

resultsRemarkable progress has been achieved in the establishment of the national AMR program, which is guided by the WHO Global Laboratory AMR Surveillance System (GLASS) in Uganda. A functional national coordinating center for AMR has been established with a supporting designated reference laboratory. WHONET software for AMR data management has been installed in the surveillance sites and laboratory staff trained on data quality assurance. Uganda has progressively submitted data to the WHO GLASS reporting system. Of the 19,216 isolates from WHO GLASS priority specimens collected from October 2015 to June 2020, 22.95% (n=4411) had community-acquired infections, 9.46% (n=1818) had hospital-acquired infections, and 68.57% (n=12,987) had infections of unknown origin. The highest proportion of the specimens was blood (12,398/19,216, 64.52%), followed by urine (5278/19,216, 27.47%) and stool (1266/19,216, 6.59%), whereas the lowest proportion was urogenital swabs (274/19,216, 1.4%). The mean age was 19.1 (SD 19.8 years), whereas the median age was 13 years (IQR 28). Approximately 49.13% (9440/19,216) of the participants were female and 50.51% (9706/19,216) were male. Participants with community-acquired infections were older (mean age 28, SD 18.6 years; median age 26, IQR 20.5 years) than those with hospital-acquired infections (mean age 17.3, SD 20.9 years; median age 8, IQR 26 years). All gram-negative (Escherichia coli, Klebsiella pneumoniae, and Neisseria gonorrhoeae) and gram-positive (Staphylococcus aureus and Enterococcus sp) bacteria with AST showed resistance to each of the tested antibiotics.

conclusionsUganda is the first African country to implement a structured national AMR surveillance program in alignment with the WHO GLASS. The reported AST data indicate very high resistance to the recommended and prescribed antibiotics for treatment of infections. More effort is required regarding quality assurance of laboratory testing methodologies to ensure optimal adherence to WHO GLASS-recommended pathogen-antimicrobial combinations. The current AMR data will inform the development of treatment algorithms and clinical guidelines.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsAdolescentAdultChildDrug Resistance, BacterialFemaleHumansMaleUgandaWorld Health OrganizationYoung AdultAnti-Bacterial AgentsAnti-Infective Agentsanalysisantibioticantimicrobialantimicrobial resistancebacteriacollectiondatafeasibilityimplementationlaboratorymicrobiologyprogressresistancesurveillanceUgandaWHO

Identifiers

PMID34673531
PMCPMC8569544
OpenAlexW3191004595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.